Supernus Non Current Liabilities Total from 2010 to 2024
SUPN Stock | USD 30.83 0.56 1.85% |
Non Current Liabilities Total | First Reported 2009-12-31 | Previous Quarter 85.4 M | Current Value 197.3 M | Quarterly Volatility 194.4 M |
Check Supernus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Supernus main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.1 M, Interest Expense of 2.3 M or Total Revenue of 637.9 M, as well as many exotic indicators such as Price To Sales Ratio of 2.47, Dividend Yield of 0.0 or PTB Ratio of 1.51. Supernus financial statements analysis is a perfect complement when working with Supernus Pharmaceuticals Valuation or Volatility modules.
Supernus | Non Current Liabilities Total |
Latest Supernus Pharmaceuticals' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Supernus Pharmaceuticals over the last few years. It is Supernus Pharmaceuticals' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Supernus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
Timeline |
Supernus Non Current Liabilities Total Regression Statistics
Arithmetic Mean | 175,583,021 | |
Geometric Mean | 88,852,200 | |
Coefficient Of Variation | 108.66 | |
Mean Deviation | 155,031,484 | |
Median | 75,607,060 | |
Standard Deviation | 190,781,540 | |
Sample Variance | 36397.6T | |
Range | 544.5M | |
R-Value | 0.58 | |
Mean Square Error | 26151T | |
R-Squared | 0.33 | |
Significance | 0.02 | |
Slope | 24,611,516 | |
Total Sum of Squares | 509566.3T |
Supernus Non Current Liabilities Total History
About Supernus Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Supernus Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Supernus Pharmaceuticals investors use historical funamental indicators, such as Supernus Pharmaceuticals's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Supernus Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Supernus Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Supernus Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Supernus Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Supernus Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Non Current Liabilities Total | 197.3 M | 179.2 M |
Currently Active Assets on Macroaxis
LAAC | Lithium Americas Corp | |
F | Ford Motor | |
CHPT | ChargePoint Holdings | |
AXL | American Axle Manufacturing | |
ICLN | iShares Global Clean |
Check out the analysis of Supernus Pharmaceuticals Correlation against competitors. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Supernus Stock analysis
When running Supernus Pharmaceuticals' price analysis, check to measure Supernus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Supernus Pharmaceuticals is operating at the current time. Most of Supernus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Supernus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Supernus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Supernus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is Supernus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share 0.02 | Revenue Per Share 11.14 | Quarterly Revenue Growth (0.02) | Return On Assets 0.0056 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.